담관암 치료제 시장 : 규모, 점유율, 성장, 산업 분석, 지역 인사이트 및 예측(2026-2034년)

Growth Factors of cholangiocarcinoma drugs Market

The global cholangiocarcinoma drugs market is witnessing significant growth due to increasing clinical focus on rare and aggressive biliary tract cancers. Cholangiocarcinoma, a cancer originating in the bile ducts, has historically been treated with chemotherapy; however, advancements in precision medicine, biomarker testing, immunotherapy, and targeted therapies are transforming the treatment landscape. Growing adoption of genomic profiling is enabling physicians to identify patients with FGFR2 fusions, IDH1 mutations, HER2 expression, and other molecular alterations, leading to more personalized treatment approaches and improved clinical outcomes.

Market Size and Forecast

The global cholangiocarcinoma drugs market was valued at USD 1.29 billion in 2025. The market is projected to reach USD 1.49 billion in 2026 and further expand to USD 3.78 billion by 2034, registering a CAGR of 12.34% during the forecast period (2026-2034).

North America dominated the global market with a 39.53% market share in 2025, supported by advanced healthcare infrastructure, strong adoption of biomarker testing, and rapid uptake of newly approved therapies.

Market Trends

Increasing Adoption of Biomarker-Driven Targeted Therapies

One of the most significant trends in the market is the growing use of biomarker-based treatment strategies. Molecular profiling enables healthcare providers to identify specific genetic alterations such as FGFR2 fusions, IDH1 mutations, and HER2-positive tumors, allowing the use of highly targeted therapies instead of traditional chemotherapy alone.

The growing development of drugs such as lirafugratinib, pemigatinib, and zanidatamab highlights the industry's shift toward personalized medicine and precision oncology.

Market Drivers

Rising Adoption of Precision Medicine

Precision medicine has become a major growth driver in the cholangiocarcinoma drugs market. Increasing integration of genomic testing into clinical practice allows physicians to select therapies based on individual tumor characteristics. This approach improves treatment effectiveness while supporting demand for innovative targeted therapies.

Growing investments by pharmaceutical companies in FGFR inhibitors, IDH1 inhibitors, HER2-targeted therapies, and immunotherapies are further strengthening market growth.

Market Restraints

Small Patient Population

Despite advancements in treatment, cholangiocarcinoma remains a rare cancer. The relatively small patient pool limits the commercial potential of many therapies and creates challenges in patient recruitment for clinical trials.

The withdrawal of certain drug programs due to enrollment difficulties demonstrates how the rarity of the disease can affect both clinical development and commercial viability.

Market Opportunities

Expansion Through New Regulatory Approvals

Regulatory approvals for innovative therapies are creating substantial growth opportunities in the market. New approvals for targeted therapies and immunotherapies are expanding treatment options beyond conventional chemotherapy.

The approval of therapies targeting HER2-positive, FGFR2-driven, and IDH1-mutated cholangiocarcinoma is opening new treatment segments and encouraging greater investment in precision oncology.

Market Challenges

High Treatment Costs

The high cost of targeted therapies and specialty oncology drugs remains a significant challenge. Since many of these treatments are designed for small biomarker-defined populations, their prices are often substantially higher than conventional therapies.

Affordability concerns, reimbursement challenges, and healthcare budget pressures may restrict broader adoption, particularly in developing markets.

Segmentation Analysis

By Therapy

The Chemotherapy segment dominated the market in 2025 due to its widespread use as a first-line treatment for advanced and unresectable cholangiocarcinoma. However, the Immunotherapy segment is expected to witness the fastest growth with a CAGR of 26.01% during the forecast period.

By Drug Class

The Antimetabolites segment held the largest market share in 2025, primarily due to the extensive use of gemcitabine-based treatment regimens. The PD-L1 Inhibitors segment is anticipated to grow rapidly at a CAGR of 41.88%.

By Disease Indication

Advanced/Recurrent Cholangiocarcinoma accounted for the largest share in 2025 because most patients are diagnosed at advanced stages when systemic drug treatment becomes necessary.

By Age Group

The Adult Segment dominated the market owing to the significantly higher prevalence of cholangiocarcinoma among adults and elderly populations.

By Type

Branded Drugs held the largest market share because most innovative therapies remain under patent protection and face limited generic competition.

By Route of Administration

The Parenteral Segment dominated the market due to the extensive use of intravenous chemotherapy, immunotherapy, and antibody-based treatments.

By Distribution Channel

Hospital Pharmacies represented the leading distribution channel, supported by the specialist oncology care required for cholangiocarcinoma treatment.

Regional Analysis

North America

North America remained the largest regional market, reaching USD 0.51 billion in 2025. The region benefits from advanced diagnostic capabilities, widespread biomarker testing, and early adoption of innovative therapies.

The U.S. market is estimated to reach approximately USD 0.54 billion in 2026, accounting for around 36.12% of global revenue.

Europe

Europe is projected to grow at a CAGR of 10.78% and reach USD 0.37 billion in 2026, driven by increasing incidence rates and expanding access to precision medicine.

Asia Pacific

Asia Pacific is expected to reach USD 0.40 billion in 2026, supported by a large patient population, increasing awareness, and growing investment in oncology research.

Latin America and Middle East & Africa

These regions are anticipated to experience moderate growth due to improving healthcare infrastructure and increasing access to cancer therapies.

Competitive Landscape

The cholangiocarcinoma drugs market is highly consolidated, with major companies focusing on research collaborations, product development, and regulatory approvals to strengthen their market positions.

Key players include:

• Incyte
• Innovent Biologics
• Servier
• Taiho Pharmaceutical
• Jazz Pharmaceuticals
• AstraZeneca
• Merck & Co.
• Relay Therapeutics
• Elevar Therapeutics

These companies are actively investing in targeted therapies, immunotherapies, strategic partnerships, and global expansion initiatives.

Conclusion

The global cholangiocarcinoma drugs market is entering a phase of strong expansion, driven by the increasing adoption of precision medicine and biomarker-guided therapies. The market is projected to grow from USD 1.29 billion in 2025 to USD 1.49 billion in 2026, ultimately reaching USD 3.78 billion by 2034 at a CAGR of 12.34%. Rising use of genomic profiling, growing approvals of targeted therapies, and expanding immunotherapy applications will continue to reshape treatment standards. Although challenges such as high treatment costs and a limited patient population remain, continuous innovation and regulatory support are expected to create substantial growth opportunities throughout the forecast period.

Segmentation By Therapy, Drug Class, Disease Indication, Type, Age Group, Route of Administration, Distribution Channel, and Region

By Therapy * Chemotherapy

• Immunotherapy
• Targeted Therapy
• Others

By Drug Class * Antimetabolites

• Platinum Compounds
• PD-L1 Inhibitors
• FGFR Inhibitors
• IDH1 Inhibitors
• HER2-Directed Therapies
• PD-1 Inhibitors
• Others

By Disease Indication * Intrahepatic Cholangiocarcinoma

• Perihilar Cholangiocarcinoma
• Distal Cholangiocarcinoma
• Advanced/Recurrent Cholangiocarcinoma
• Others

By Age Group * Pediatric

• Adult

By Type * Branded

• Generic

By Route of Administration * Oral

• Parenteral

By Distribution Channel * Hospital Pharmacies

• Drug Stores & Retail Pharmacies
• Online Pharmacies

By Region * North America (By Therapy, Drug Class, Disease Indication, Type, Age Group, Route of Administration, Distribution Channel, and Country)

• U.S.
• Canada
• Europe (By Therapy, Drug Class, Disease Indication, Type, Age Group, Route of Administration, Distribution Channel, and Country/Sub-region)
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Therapy, Drug Class, Disease Indication, Type, Age Group, Route of Administration, Distribution Channel, and Country/Sub-region)
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Therapy, Drug Class, Disease Indication, Type, Age Group, Route of Administration, Distribution Channel, and Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Therapy, Drug Class, Disease Indication, Type, Age Group, Route of Administration, Distribution Channel, and Country/Sub-region)
  • GCC
  • South Africa
  • Rest of Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Cholangiocarcinoma, By Key Region
• 4.2. New Product Launches, By Key Players
• 4.3. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)
• 4.4. Regulatory Scenario, By Key Countries/Regions
• 4.5. Key Start Up, By Key Regions, 2025

5. Global Cholangiocarcinoma Drugs Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Therapy
  • 5.1.1. Chemotherapy
  • 5.1.2. Immunotherapy
  • 5.1.3. Targeted Therapy
  • 5.1.4. Others
• 5.2. Market Analysis, Insights and Forecast - By Drug Class
  • 5.2.1. Antimetabolites
  • 5.2.2. Platinum Compounds
  • 5.2.3. PD-L1 Inhibitors
  • 5.2.4. FGFR Inhibitors
  • 5.2.5. IDH1 Inhibitors
  • 5.2.6. HER2-Directed Therapies
  • 5.2.7. PD-1 Inhibitors
  • 5.2.8. Others
• 5.3. Market Analysis, Insights and Forecast - By Disease Indication
  • 5.3.1. Intrahepatic Cholangiocarcinoma
  • 5.3.2. Perihilar Cholangiocarcinoma
  • 5.3.3. Distal Cholangiocarcinoma
  • 5.3.4. Advanced / Recurrent Cholangiocarcinoma
  • 5.3.5. Others
• 5.4. Market Analysis, Insights and Forecast - By Age Group
  • 5.4.1. Pediatric
  • 5.4.2. Adult
• 5.5. Market Analysis, Insights and Forecast - By Type
  • 5.5.1. Branded
  • 5.5.2. Generic
• 5.6. Market Analysis, Insights and Forecast - By Route of Administration
  • 5.6.1. Oral
  • 5.6.2. Parenteral
• 5.7. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.7.1. Hospital Pharmacies
  • 5.7.2. Drug Stores & Retail Pharmacies
  • 5.7.3. Online Pharmacies
• 5.8. Market Analysis, Insights and Forecast - Region
  • 5.8.1. North America
  • 5.8.2. Europe
  • 5.8.3. Asia Pacific
  • 5.8.4. Latin America
  • 5.8.5. Middle East & Africa

6. North America Cholangiocarcinoma Drugs Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Therapy
  • 6.1.1. Chemotherapy
  • 6.1.2. Immunotherapy
  • 6.1.3. Targeted Therapy
  • 6.1.4. Others
• 6.2. Market Analysis, Insights and Forecast - By Drug Class
  • 6.2.1. Antimetabolites
  • 6.2.2. Platinum Compounds
  • 6.2.3. PD-L1 Inhibitors
  • 6.2.4. FGFR Inhibitors
  • 6.2.5. IDH1 Inhibitors
  • 6.2.6. HER2-Directed Therapies
  • 6.2.7. PD-1 Inhibitors
  • 6.2.8. Others
• 6.3. Market Analysis, Insights and Forecast - By Disease Indication
  • 6.3.1. Intrahepatic Cholangiocarcinoma
  • 6.3.2. Perihilar Cholangiocarcinoma
  • 6.3.3. Distal Cholangiocarcinoma
  • 6.3.4. Advanced / Recurrent Cholangiocarcinoma
  • 6.3.5. Others
• 6.4. Market Analysis, Insights and Forecast - By Age Group
  • 6.4.1. Pediatric
  • 6.4.2. Adult
• 6.5. Market Analysis, Insights and Forecast - By Type
  • 6.5.1. Branded
  • 6.5.2. Generic
• 6.6. Market Analysis, Insights and Forecast - By Route of Administration
  • 6.6.1. Oral
  • 6.6.2. Parenteral
• 6.7. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.7.1. Hospital Pharmacies
  • 6.7.2. Drug Stores & Retail Pharmacies
  • 6.7.3. Online Pharmacies
• 6.8. Market Analysis, Insights and Forecast - By Country
  • 6.8.1. U.S.
  • 6.8.2. Canada

7. Europe Cholangiocarcinoma Drugs Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Therapy
  • 7.1.1. Chemotherapy
  • 7.1.2. Immunotherapy
  • 7.1.3. Targeted Therapy
  • 7.1.4. Others
• 7.2. Market Analysis, Insights and Forecast - By Drug Class
  • 7.2.1. Antimetabolites
  • 7.2.2. Platinum Compounds
  • 7.2.3. PD-L1 Inhibitors
  • 7.2.4. FGFR Inhibitors
  • 7.2.5. IDH1 Inhibitors
  • 7.2.6. HER2-Directed Therapies
  • 7.2.7. PD-1 Inhibitors
  • 7.2.8. Others
• 7.3. Market Analysis, Insights and Forecast - By Disease Indication
  • 7.3.1. Intrahepatic Cholangiocarcinoma
  • 7.3.2. Perihilar Cholangiocarcinoma
  • 7.3.3. Distal Cholangiocarcinoma
  • 7.3.4. Advanced / Recurrent Cholangiocarcinoma
  • 7.3.5. Others
• 7.4. Market Analysis, Insights and Forecast - By Age Group
  • 7.4.1. Pediatric
  • 7.4.2. Adult
• 7.5. Market Analysis, Insights and Forecast - By Type
  • 7.5.1. Branded
  • 7.5.2. Generic
• 7.6. Market Analysis, Insights and Forecast - By Route of Administration
  • 7.6.1. Oral
  • 7.6.2. Parenteral
• 7.7. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.7.1. Hospital Pharmacies
  • 7.7.2. Drug Stores & Retail Pharmacies
  • 7.7.3. Online Pharmacies
• 7.8. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.8.1. U.K.
  • 7.8.2. Germany
  • 7.8.3. France
  • 7.8.4. Italy
  • 7.8.5. Spain
  • 7.8.6. Scandinavia
  • 7.8.7. Rest of Europe

8. Asia Pacific Cholangiocarcinoma Drugs Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Therapy
  • 8.1.1. Chemotherapy
  • 8.1.2. Immunotherapy
  • 8.1.3. Targeted Therapy
  • 8.1.4. Others
• 8.2. Market Analysis, Insights and Forecast - By Drug Class
  • 8.2.1. Antimetabolites
  • 8.2.2. Platinum Compounds
  • 8.2.3. PD-L1 Inhibitors
  • 8.2.4. FGFR Inhibitors
  • 8.2.5. IDH1 Inhibitors
  • 8.2.6. HER2-Directed Therapies
  • 8.2.7. PD-1 Inhibitors
  • 8.2.8. Others
• 8.3. Market Analysis, Insights and Forecast - By Disease Indication
  • 8.3.1. Intrahepatic Cholangiocarcinoma
  • 8.3.2. Perihilar Cholangiocarcinoma
  • 8.3.3. Distal Cholangiocarcinoma
  • 8.3.4. Advanced / Recurrent Cholangiocarcinoma
  • 8.3.5. Others
• 8.4. Market Analysis, Insights and Forecast - By Age Group
  • 8.4.1. Pediatric
  • 8.4.2. Adult
• 8.5. Market Analysis, Insights and Forecast - By Type
  • 8.5.1. Branded
  • 8.5.2. Generic
• 8.6. Market Analysis, Insights and Forecast - By Route of Administration
  • 8.6.1. Oral
  • 8.6.2. Parenteral
• 8.7. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.7.1. Hospital Pharmacies
  • 8.7.2. Drug Stores & Retail Pharmacies
  • 8.7.3. Online Pharmacies
• 8.8. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.8.1. China
  • 8.8.2. Japan
  • 8.8.3. India
  • 8.8.4. Southeast Asia
  • 8.8.5. Australia
  • 8.8.6. Rest of Asia Pacific

9. Latin America Cholangiocarcinoma Drugs Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Therapy
  • 9.1.1. Chemotherapy
  • 9.1.2. Immunotherapy
  • 9.1.3. Targeted Therapy
  • 9.1.4. Others
• 9.2. Market Analysis, Insights and Forecast - By Drug Class
  • 9.2.1. Antimetabolites
  • 9.2.2. Platinum Compounds
  • 9.2.3. PD-L1 Inhibitors
  • 9.2.4. FGFR Inhibitors
  • 9.2.5. IDH1 Inhibitors
  • 9.2.6. HER2-Directed Therapies
  • 9.2.7. PD-1 Inhibitors
  • 9.2.8. Others
• 9.3. Market Analysis, Insights and Forecast - By Disease Indication
  • 9.3.1. Intrahepatic Cholangiocarcinoma
  • 9.3.2. Perihilar Cholangiocarcinoma
  • 9.3.3. Distal Cholangiocarcinoma
  • 9.3.4. Advanced / Recurrent Cholangiocarcinoma
  • 9.3.5. Others
• 9.4. Market Analysis, Insights and Forecast - By Age Group
  • 9.4.1. Pediatric
  • 9.4.2. Adult
• 9.5. Market Analysis, Insights and Forecast - By Type
  • 9.5.1. Branded
  • 9.5.2. Generic
• 9.6. Market Analysis, Insights and Forecast - By Route of Administration
  • 9.6.1. Oral
  • 9.6.2. Parenteral
• 9.7. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.7.1. Hospital Pharmacies
  • 9.7.2. Drug Stores & Retail Pharmacies
  • 9.7.3. Online Pharmacies
• 9.8. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 9.8.1. Brazil
  • 9.8.2. Mexico
  • 9.8.3. Rest of Latin America

10. Middle East & Africa Cholangiocarcinoma Drugs Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Therapy
  • 10.1.1. Chemotherapy
  • 10.1.2. Immunotherapy
  • 10.1.3. Targeted Therapy
  • 10.1.4. Others
• 10.2. Market Analysis, Insights and Forecast - By Drug Class
  • 10.2.1. Antimetabolites
  • 10.2.2. Platinum Compounds
  • 10.2.3. PD-L1 Inhibitors
  • 10.2.4. FGFR Inhibitors
  • 10.2.5. IDH1 Inhibitors
  • 10.2.6. HER2-Directed Therapies
  • 10.2.7. PD-1 Inhibitors
  • 10.2.8. Others
• 10.3. Market Analysis, Insights and Forecast - By Disease Indication
  • 10.3.1. Intrahepatic Cholangiocarcinoma
  • 10.3.2. Perihilar Cholangiocarcinoma
  • 10.3.3. Distal Cholangiocarcinoma
  • 10.3.4. Advanced / Recurrent Cholangiocarcinoma
  • 10.3.5. Others
• 10.4. Market Analysis, Insights and Forecast - By Age Group
  • 10.4.1. Pediatric
  • 10.4.2. Adult
• 10.5. Market Analysis, Insights and Forecast - By Type
  • 10.5.1. Branded
  • 10.5.2. Generic
• 10.6. Market Analysis, Insights and Forecast - By Route of Administration
  • 10.6.1. Oral
  • 10.6.2. Parenteral
• 10.7. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.7.1. Hospital Pharmacies
  • 10.7.2. Drug Stores & Retail Pharmacies
  • 10.7.3. Online Pharmacies
• 10.8. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 10.8.1. GCC
  • 10.8.2. South Africa
  • 10.8.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. Incyte
  • 11.2.2. Innovent Biologics
  • 11.2.3. Servier
  • 11.2.4. Taiho Pharmaceutical
  • 11.2.5. Jazz Pharmaceuticals
  • 11.2.6. AstraZeneca
  • 11.2.7. Merck & Co., Inc.,
  • 11.2.8. Relay Therapeutics
  • 11.2.9. Elevar Therapeutics
  • 11.2.10. Eisai Inc.